Biosimilarity vs. “Cognitive Dissonance”: The Ongoing Challenges to New FDA Pathway
This article was originally published in RPM Report
FDA is still awaiting its first biosimilar product application – and there is no reason to expect a flood of products any time soon. The new pathway faces legal, logistical and resource obstacles. But the most important barrier may be the need for a mindset change.